

Status: Currently Official on 14-Feb-2025  
Official Date: Official Prior to 2013  
Document Type: USP Monographs  
DocId: GUID-3B91E17F-C227-4CCA-A4BE-B71B7721C74D\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M14113\\_01\\_01](https://doi.org/10.31003/USPNF_M14113_01_01)  
DOI Ref: b5lj5

© 2025 USPC  
Do not distribute

# Cefpodoxime Proxetil Tablets

» Cefpodoxime Proxetil Tablets contain an amount of Cefpodoxime Proxetil equivalent to not less than 90.0 percent and not more than 110.0 percent of the labeled amount of cefpodoxime ( $C_{15}H_{17}N_5O_6S_2$ ).

**Packaging and storage**—Preserve in tight containers, at controlled room temperature.

**USP REFERENCE STANDARDS (11)**—  
[USP Cefpodoxime Proxetil RS](#)

**Identification**—The retention times of the cefpodoxime proxetil *R*-epimer peak and the cefpodoxime proxetil *S*-epimer peak in the chromatogram of the *Assay preparation* correspond to those in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.

**DISSOLUTION (711)**—

*Medium*—Dissolve 54.5 g of glycine and 42.6 g of sodium chloride in about 500 mL of water in a 1000-mL volumetric flask. Cautiously add, with swirling, 14.2 mL of hydrochloric acid, and allow to cool. Dilute with water to volume, and mix. Transfer 50 mL of this stock solution to a flask, and dilute with water to 900 mL to obtain a solution having a pH of  $3.0 \pm 0.1$ . [NOTE—If necessary, adjust the pH of the stock solution with 10 N sodium hydroxide so that when 50 mL is diluted with water to 900 mL the pH of the *Dissolution Medium* is  $3.0 \pm 0.1$ .]

*Apparatus 2*: 75 rpm.

*Time*: 30 minutes.

*Procedure*—Determine the amount of cefpodoxime ( $C_{15}H_{17}N_5O_6S_2$ ) dissolved by employing UV absorption at about 259 nm on filtered portions of the solution under test in comparison with a Standard solution having a known concentration of [USP Cefpodoxime Proxetil RS](#) prepared by dissolving an accurately weighed portion in a small volume of methanol and diluting quantitatively with *Dissolution Medium*.

*Tolerances*—Not less than 70% (*Q*) of the labeled amount of cefpodoxime ( $C_{15}H_{17}N_5O_6S_2$ ) is dissolved in 30 minutes.

**UNIFORMITY OF DOSAGE UNITS (905)**: meet the requirements.

**WATER DETERMINATION (921)**: not more than 5.0%.

**Assay**—

*Mobile phase, Diluent, and Chromatographic system*—Prepare as directed in the *Assay* under [Cefpodoxime Proxetil](#).

*Standard preparation*—Transfer about 30 mg of [USP Cefpodoxime Proxetil RS](#), accurately weighed, to a 50-mL volumetric flask, dissolve in 5 mL of methanol, dilute with *Diluent* to volume, and mix. Transfer 5.0 mL of this solution to a 100-mL volumetric flask, dilute with *Diluent* to volume, and mix. Pass through a filter having a 0.45-μm or finer porosity.

*Assay preparation*—Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 50 mg of cefpodoxime to a 100-mL volumetric flask. Dissolve in 40 mL of *Diluent*, sonicating for 5 minutes. Cool to room temperature, dilute with *Diluent* to volume, and mix. Transfer 5.0 mL of this solution to a 100-mL volumetric flask, dilute with *Diluent* to volume, mix, and pass through a filter having a 0.45-μm or finer porosity.

*Procedure*—Separately inject equal volumes (about 20 μL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg of cefpodoxime ( $C_{15}H_{17}N_5O_6S_2$ ) in the portion of Tablets taken by the formula:

$$2CP(r_U/r_S)$$

in which *C* is the concentration, in mg per mL, of [USP Cefpodoxime Proxetil RS](#) in the *Standard preparation*; *P* is the designated potency, in μg per mg, of cefpodoxime ( $C_{15}H_{17}N_5O_6S_2$ ) in [USP Cefpodoxime Proxetil RS](#); and *r<sub>U</sub>* and *r<sub>S</sub>* are the sums of the peak responses for cefpodoxime proxetil *S*-epimer and cefpodoxime proxetil *R*-epimer obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question               | Contact                                       | Expert Committee          |
|------------------------------|---|---------------------------|
| CEFPODOXIME PROXETIL TABLETS | <a href="#">Documentary Standards Support</a> | SM12020 Small Molecules 1 |

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 47(1)

**Current DocID: GUID-3B91E17F-C227-4CCA-A4BE-B71B7721C74D\_1\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M14113\\_01\\_01](https://doi.org/10.31003/USPNF_M14113_01_01)**

**DOI ref: [b5lj5](#)**

OFFICIAL